Author:
Shi Xue-feng,Yu Qi,Wang Kai-bo,Fu Yi-dong,Zhang Shun,Liao Zhen-yun,Li Yan,Cai Ting
Abstract
AbstractGastric cancer (GC) remains the third leading cause of cancer-related mortality in the world, and ninety-five percent of GC are stomach adenocarcinomas (STAD). The active ingredients of Croci Stigma, such as Isorhamnetin, Crocin, Crocetin and Kaempferol, all have antitumor activity. However, their chemical and pharmacological profiles remain to be elusive. In this study, network pharmacology was used to characterize the action mechanism of Croci Stigma. All compounds were obtained from the traditional Chinese medicine systems pharmacology (TCMSP) database, and active ingredients were selected by their oral bioavailability and drug-likeness index. The targets of Croci Stigma active ingredients were obtained from the traditional Chinese medicine integrated database (TCMID), whereas the related genes of STAD were obtained from DisGeNET platform. Cytoscape was used to undertake visual analyses of the Drug Ingredients–Gene Symbols–Disease (I–G–D) network, and 2 core genes including MAPK14, ERBB3 were obtained, which are the predicted targets of isorhamnetin (IH) and quercetin, respectively. Data analysis from TCGA platform showed that MAPK14 and ERBB3 all upregulated in STAD patients, but only the effect of MAPK14 expression on STAD patients’ survival was significant. Molecular docking showed that IH might affect the function of MAPK14 protein, and then the underlying action mechanisms of IH on STAD were experimentally validated using human gastric cancer cell line, HGC-27 cells. The results showed that IH can inhibit cell proliferation, migration, clonal formation, and arrest cell cycle, but promote the apoptosis of HGC-27 cells. qRT-PCR data demonstrated that IH downregulated the MAPK14 mRNA expression and EMT related genes. WB results showed that IH regulates MAPK/mTOR signaling pathway. These findings suggest that IH has the therapeutic potential for the treatment of STAD.
Funder
Kunlun Elite of Qinghai Province High-End Innovation and Entrepreneurship leading Talents
Qinghai Science and Technology Department
Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
2. Eusebi, L. H., Telese, A., Marasco, G., Bazzoli, F. & Zagari, R. M. Gastric cancer prevention strategies: A global perspective. J. Gastroenterol. Hepatol. 35(9), 1495–1502 (2020).
3. Hsiao, Y. J. et al. Application of artificial intelligence-driven endoscopic screening and diagnosis of gastric cancer. World J. Gastroenterol. 27(22), 2979–2993 (2021).
4. Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C. & Lordick, F. Gastric cancer. Lancet 396(10251), 635–648 (2020).
5. Rawla, P. & Barsouk, A. Epidemiology of gastric cancer: Global trends, risk factors and prevention. Prz. Gastroenterol. 14(1), 26–38 (2019).